Moderna (MRNA) Gains FDA Nod for Next-Gen COVID-19 Vaccine Targeting LP.8.1 Variant

Moderna, Inc. (NASDAQ:MRNA) ranks among the best mid-cap stocks with huge upside potential. Moderna, Inc. (NASDAQ:MRNA) reported on August 27 that the US Food and Drug Administration had granted supplementary Biologics License Applications for its 2025-2026 COVID-19 vaccination compositions aimed at the LP.8.1 variant of SARS-CoV-2.

All adults 65 years of age and over, as well as individuals aged 6 months to 64 with at least one underlying disease that raises the risk of severe COVID-19 outcomes, were approved to receive the revised Spikevax vaccination.

Additionally, the updated vaccine composition complies with FDA recommendations that monovalent JN.1 lineage, preferably the LP.8.1 variation, be used in the development of COVID-19 vaccines.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company dedicated to the discovery, development, and commercialization of mRNA-based medicines and vaccines. The company received solid recognition for its COVID-19 vaccine, which was one of the first mRNA vaccines to be created and delivered worldwide.

While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.